The Efficacy of Brucea javanica Oil Emulsion Injection as Adjunctive Therapy for Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis

Table 1

Baseline characteristics of included studies.

Study ID	Age	Sex		N (B/C)	Intervention		Outcome	Criteria for outcome		KPS	Stage
		Male	Female		BJOEI group	Control group		Efficacy	Adverse event
Wang and Shu; 2007	27–72	22	18	20/20	GP + BJOEI 30 ml	GP	Efficacy rate	WHO criteria	—	>70	IIIB-IV
Chen et al. 2010	38–71	62	24	45/41	GP + BJOEI 30–40 ml	GP	Efficacy rate; quality of life; gastrointestinal reaction; myelosuppression	WHO criteria	WHO recommendations	>60	IIIB-IV
Tong et al. 2011	39–76	33	30	33/30	GP + BJOEI 30 ml	GP	Efficacy rate; quality of life; gastrointestinal reaction; myelosuppression	WHO criteria	WHO recommendations	≥60	IIIB-IV
Wang et al. 2012	52–74	94	42	68/68	GP + BJOEI 30 ml	GP	Efficacy rate; quality of life; gastrointestinal reaction	WHO criteria	WHO recommendations	>60	IV
Wang et al. 2012	32–76	77	27	52/52	GP + BJOEI 30 ml	GP	Efficacy rate	WHO criteria	—	≥60	III-IV
Wang and Li 2012	38–75	49	31	40/40	GP + BJOEI 30 ml	GP	Efficacy rate; quality of life; myelosuppression	RECST	—	≥60	IIIB-IV
Sun et al. 2014	40–70	74	46	60/60	GP + BJOEI 30 ml	GP	Efficacy rate	WHO criteria	—	>60	III-IVB
Wang et al. 2015	35–75	52	28	40/40	GP + BJOEI 20–30 ml	GP	Efficacy rate; myelosuppression	WHO criteria	WHO recommendations	≥60	III-IV
Ye et al. 2015	—	68	39	54/53	GP + BJOEI 30 ml	GP	Efficacy rate	RECST	—	>60	III-IV
Fu et al. 2009	29–71	40	21	31/30	TP + BJOEI 10 ml	TP	Efficacy rate; quality of life; gastrointestinal reaction; myelosuppression	WHO criteria	WHO recommendations	>60	IIIB-IV
Lin et al. 2012	30–70	41	15	28/28	TP + BJOEI 30 ml	TP	Efficacy rate; quality of life; myelosuppression	WHO criteria	WHO recommendations	≥70	IIIB-IV
Zhu 2014	40–70	25	11	18/18	TP + BJOEI 10 ml	TP	Efficacy rate; gastrointestinal reaction; myelosuppression	RECST	WHO recommendations	≥70	IIIB-IV
Wang 2015	35–75	58	22	40/40	TP + BJOEI 30 ml	TP	Efficacy rate; quality of life; gastrointestinal reaction; myelosuppression	WHO criteria	WHO recommendations	>70	IIIA-IV
Du and Shi 2006	27–72	76	37	57/56	NP + BJOEI 30 ml	NP	Efficacy rate; myelosuppression	WHO criteria	—	≥70	IIIB-IV
Wang et al. 2011	32–75	42	30	36/36	NP + BJOEI 40 ml	NP	Efficacy rate; quality of life	WHO criteria	—	>60	IIIB-IV
Dong et al. 2009	60–79	42	26	34/34	NP + BJOEI 30 ml	NP	Efficacy rate; quality of life; myelosuppression	WHO criteria	—	72–74	IIIA-IV
Ren et al. 2012	18–75	109	45	78/76	NP + BJOEI 40 ml	NP	Efficacy rate;	WHO criteria	—	>60	III-IV
Cui et al. 2010	—	32	18	25/25	DP + BJOEI 30 ml	DP	Efficacy rate	WHO criteria	—	≥60	IIIA-IV
Niu et al. 2011	≤75	37	11	24/24	DP + BJOEI 30 ml	DP	Efficacy rate; quality of life	RECST	—	≥60	III-IV
Ke et al. 2012	48–78	291	277	284/284	DP + BJOEI <70 ml	DP	Efficacy rate; quality of life; myelosuppression	WHO criteria	—	>60	IIIA-IIIB
Cai et al. 2015	42–78	64	48	56/56	DP + BJOEI 30 ml	DP	Efficacy rate; quality of life	WHO criteria	—	≥60	III-IV

BJOEI, Brucea javanica oil emulsion injection; GP, gemcitabine + platinum; TP, paclitaxel + platinum; NP, vinorelbine + platinum; DP, docetaxel + platinum; KPS, Karnofsky Performance Score.